reports
Resolutions from the Annual General Meeting 2026
Resolutions from the Annual General Meeting 2026 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025Approval of the Remuneration Report for 2025 (advisory vote)Approval of the remuneration of membe...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO...
Novonesis issues EUR 1.7 billion senior unsecured notes
Novonesis issues EUR 1.7 billion senior unsecured notes On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026. The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%. ...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Novonesis named a Great Employer to Work For in North Carolina
Novonesis named a Great Employer to Work For in North Carolina Franklinton, North Carolina, March 09, 2026 (GLOBE NEWSWIRE) -- , a global leader in biosolutions, has been named a 2026 Great Employer to Work for in North Carolina by Best Companies Group (BCG), marking the company’s first time earning this prestigious recognition. BCG is a trusted leader in workplace culture research and recognition, distinguishing top companies around the United States for more than 20 years. The honor is based entirely on confidential employee feedback and a comprehensive evaluation of workplace practices...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment
Invitation to the 2026 Annual General Meeting
Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...
Novonesis delivered strong organic sales growth of 7% in 2025
Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...
Novonesis' Annual Report 2025
Novonesis' Annual Report 2025 Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO:”In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of ...
Novonesis delivered 8% organic sales growth in the first nine months o...
Novonesis delivered 8% organic sales growth in the first nine months of 2025 Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO: "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and i...
8% organic sales growth after first nine months. Full-year organic sal...
8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards. Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quar...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen matching shares program and the legacy Chr. Hansen 2023 restricted stock units (RSU) program. Attachment ...
Noma and Novonesis partner to scale deliciousness
Noma and Novonesis partner to scale deliciousness Noma and Novonesis partner to scale deliciousnessNoma, hailed as one of the world’s best restaurants, is joining forces with Novonesis, the global leader in biosolutions, to take deliciousness to the next level. Together, they’re fusing culinary craft with biology to create flavors and products that are healthier, tastier, and better for the planet. COPENHAGEN, 23 October 2025: Innovation pushes boundaries and, at times, returns to the beginning. For thousands of years, we have used biology to craft our rich tapestry of food and beverage tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.